From a therapeutic perspective, targeting key molecular drivers of spontaneous neurogenesis—including NGF, GDNF, VEGF, and the TGF-β/Smad3 pathway underlying MNT—represents a promising approach to mitigating the adverse effects of tumor innervation. This evidence concerns the gene TGFB1 and neoplasm.